Clinical features and correlates of gemcitabine-associated lung injury: Findings from the RADAR project

Cancer

Volumn 106, Issue 9, 2006, Pages 2051-2057

  Belknap, Steven M ^a   Kuzel, Timothy M ^a   Yarnold, Paul R ^a   Slimack, Nicholas ^a   Lyons, E Allison ^a   Raisch, Dennis W ^b   Bennett, Charles L ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b University of New Mexico   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Acute lung injury; Adverse drug event; Drug toxicity; Gemcitabine

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ADVERSE EVENT REPORTING SYSTEM; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; DYSPNEA; FEMALE; FEVER; FOOD AND DRUG ADMINISTRATION; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; LUNG CANCER; LUNG INFILTRATE; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RESEARCH ON ADVERSE DRUG EVENTS AND REPORTS PROJECT;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG; MALE; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 33646353444     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21808     Document Type: Article

References (65)

1. Merriman RL, Hertel LW, Schultz RM, et al. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs. 1996;14:243-247.
2. Available at URL: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi? cid=60749.
3. Available at URL: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi? cid=511889.
4. Gemzar (gemcitabine HCl) Package Insert. Indianapolis: Eli Lilly.
5. Friedberg JW, Neuberg D, Kim H, et al. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer. 2003;98:978-982.
6. Bredenfeld H, Franklin J, Nogova L, et al. German Hodgkin's Lymphoma Study Group. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEA-COPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2004;22:2424-2429.
7. Bennett CL, Nebeker JR, Lyons EA, et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA. 2005;293:2131-2140.
8. Ladewski LA, Belknap SM, Nebeker JR, et al. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol. 2003;21:3859-3866.
9. Yarnold PR, Soltysik RC. Optimal data analysis: a guidebook with software for Windows. Washington, DC: APA Books, 2004.
10. Ek T, Jarfelt M, Mellander L, et al. Proinflammatory cytokines mediate the systemic inflammatory response associated with high-dose cytarabine treatment in children. Med Pediatr Oncol. 2001;37:459-464.
11. Chiche D, Pico JL, Bernaudin JF, et al. Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF. Ear Cytokine Netw. 1993;4:147-151.
12. Levitt ML, Kassem B, Gooding WE, et al. Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms. Lung Cancer. 2004;43:335-344.
13. Rube CE, Rodemann HP, Rube C. The relevance of cytokines in the radiation-induced lung reaction. Experimental basis and clinical significance. Strahlenther Onkol. 2004;180:541-549.
14. Rube CE, Wilfert F, Uthe D, et al. Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. Radiother Oncol. 2004;72:231-241.
15. Ogura K, Ohta S, Ohmori T, et al. Vinca alkaloids induce granulocyte-macrophage colony stimulating factor in human peripheral blood mononuclear cells. Anticancer Res. 2000;20:2383-2388.
16. Palma JP, Aggarwal SK. Cisplatin and carboplatin-mediated activation of murine peritoneal macrophages in vitro: production of interleukin-1 alpha and tumor necrosis factor-alpha. Anticancer Drugs. 1995;6:311-316.
17. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002;110:835-842.
18. Allen JN, Moore SA, Wewers MD. Taxol enhances but does not induce interleukin-1 beta and tumor necrosis factor-alpha production. J Lab Clin Med. 1993;122:374-381.
19. Trontell AE. The RADAR project and the FDA. JAMA. 2005;294:1206.
20. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med. 1998;128:541-544.
21. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342:1773-1777.
22. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;351:1403-1408.
23. Blackstock AW, Socinski MA, Gu L, et al. Initial pulmonary toxicity evaluation of chemoradiotherapy (CRT) utilizing 74 Gy 3-dimensional (3-D) thoracic radiation in stage III non-small cell lung cancer (NSCLC): a Cancer and Leukemia Group B (CALGB) randomized phase II trial [Abstr 7060]. Am Soc Clin Oncol. 2005.
24. Vander Els NJ, Miller V. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest. 1998;114:1779-1781.
25. Barlesi F, Pujol JL. Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials. Lung Cancer. 2005;49:289-298.
26. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997;80:286-291.
27. Dumontet C, Morschhauser F, Solal-Celigny P, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol. 2001;113:772-778.
28. De Pas T, Curigliano G, Franceschelli L, Catania C, Spaggiari L, de Braud F. Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol 2001;12:1651-1652.
29. Pulkkanen K, Kataja V, Johansson R. Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report. J Chemother. 2003;15:287-289.
30. Biswas S, Nik S, Corrie PG. Severe gemcitabine-induced capillary-leak syndrome mimicking cardiac failure in a patient with advanced pancreatic cancer and high-risk cardiovascular disease. Clin Oncol (R Coll Radiol). 2004;16:577-579.
31. Briasoulis E, Froudarakis M, Milionis HJ, Peponis I, Constantopoulos S, Pavlidis N. Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support. Respiration. 2000;67:680-683.
32. Briasoulis E, Pavlidis N. Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist. 2001;6:153-161.
33. Furuse K. Gemcitabine in the treatment of non-small cell lung cancer for elderly patients. Gan To Kagaku Ryoho. 1999;26:890-897.
34. Attar EC, Ervin T, Janicek M, Deykin A, Godleski J. Case 3. Acute interstitial pneumonitis related to gemcitabine. J Clin Oncol. 2000;18:693-698.
35. Chen YM, Perng RP, Yang KY, et al. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer. Chest 2000;117:1583-1589.
36. Boiselle PM, Morrin MM, Huberman MS. Gemcitabine pulmonary toxicity: CT features. J Comput Assist Tomogr. 2000;24:977-980.
37. Rebattu P, Quantin X, Ardiet C, et al. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer. 2001;33:277-287.
38. Rosado MF, Kett DH, Schein RM, Baraona FJ, Sridhar KS. Severe pulmonary toxicity in a patient treated with gemcitabine. Am J Clin Oncol. 2002;25:31-33.
39. Gupta N, Ahmed I, Steinberg H, Patel D, Nissel-Horowitz S, Mehrotra B. Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol. 2002;25:96-100.
40. Hammerer V, Schmitz N, Pauli G, Quoix E. Interstitial lung disease in a patient given gemcitabine. Rev Pneumol Clin. 2002;58:23-26.
41. Roychowdhury DF, Cassidy CA, Peterson P, Arning M. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs. 2002;20:311-315.
42. Sabria-Trias J, Bonnaud F, Sioniac M. Severe interstitial pneumonitis related to gemcitabine. Rev Mal Respir. 2002;19:645-647.
43. Chen YM, Perng RP, Lin WC, Wu HW, Tsai CM, Whang-Peng J. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol. 2002;25:509-512.
44. Chen YM, Perng RP, Chen MC, Tsai CM, Ming-Liu J, Whang-Peng J. A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older. Lung Cancer. 2003;40:221-226.
45. Barlesi F, Doddoli C, Gimenez C, Greillier L, Lima G, Kleisbauer JP. Acute pulmonary toxicity due to gemcitabine: a role for asbestos exposure? Rev Mal Respir. 2003;20;201-206.
46. Kouroussis C, Mavroudis D, Kakolyris S, et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer. 2004;44:363-368.
47. Aguiar Bujanda D, Aguiar Morales J, Bohn Sarmiento U. Bronchiolitis obliterans organizing pneumonia induced by chemotherapy. Arch Bronconeumol. 2004;40:290.
48. Sabria-Trias J, Bonnaud F, Sioniac M. Severe interstitial pneumonitis related to gemcitabine. Rev Mal Respir. 2002;19:645-647.
49. Mommens V, Bosquee L, D'Orio V. Clinical case of the month. Pulmonary toxicity due to gemcitabine for NSCLC with brain metastasis. Rev Med Liege. 2003;58:123-126.
50. Girard T, Mouthon L, Boaziz C, Andre MH, Guillevin L. Favorable outcome of gemcitabine-induced respiratory distress syndrome. Ann Med Interne (Paris). 2000;151:306-308.
51. de Lavigerie B, Joasson JM. Acute respiratory distress syndrome after antineoplastic chemotherapy. Probable role of gemcitabine. Presse Med. 2001;30:851-854.
52. Maniwa K, Tanaka E, Inoue T, et al. An autopsy case of acute pulmonary toxicity associated with gemcitabine. Intern Med. 2003;42:1022-1025.
53. Dunsford ML, Mead GM, Bateman AC, Cook T, Tung K. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol. 1999;10:943-947.
54. Ciotti R, Belotti G, Facchi E, Cantu A, D'Amico A, Gatti C. Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine. Ann Oncol. 1999;10:997.
55. Marruchella A, Tondini M. Gemcitabine toxicity. Chest. 1999;116:1491.
56. Linskens RK, Golding RP, van Groeningen CJ, Giaccone G. Severe acute lung injury induced by gemcitabine. Neth J Med. 2000;56:232-235.
57. Kouroussis C, Mavroudis D, Kakolyris S, et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer. 2004;44:363-368.
58. Popa IE, Stewart K, Smith FP, Rizvi NA. A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma. Cancer. 2002;95:1714-1719.
59. Chen YM, Perng RP, Yang KY, et al. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer. Chest. 2000;117:1583-1589.
60. Li J, Juliar B, Yiannoutsos C, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol. 2005;23:1185-1191.
61. Blackstock AW, Lesser GJ, Fletcher-Steede J, et al. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:1281-1289.
62. Safran H, Dipetrillo T, Iannitti D, et al. Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial. Int J Radiat Oncol Biol Phys. 2002;54:137-141.
63. Bhatia S, Hanna N, Ansari R, et al. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV nonsmall cell lung cancer. Lung Cancer. 2002;38:73-77.
64. Vokes EE, Herndon JE 2nd, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002;20:4191-4198.
65. van Putten JW, Price A, van der Leest AH, Gregor A, Little FA, Groen HJ. A Phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res. 2003;9:2472-2477.